Wednesday, October 25, 2006
Amgen Completes Avidia Acquisition
Thousand Oaks-based Amgen has completed its acquisition of Mountain View-based Avidia, the firm said Tuesday afternoon. The previously announced acquisition was worth $290M. Avidia's lead product candidate is an inhibitor of interleukin 6, targeted at the treatment of inflammation and autoimmune diseases.